TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01228617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Following a 12-hour nicotine abstinence period, subjects receive a single 2 mg dose of their assigned nicotine replacement therapy in the morning of the treatment visit day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Following a 12-hour nicotine abstinence period, subjects receive a single 2 mg dose of their assigned nicotine replacement therapy in the morning of the treatment visit day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Following a 12-hour nicotine abstinence period, subjects receive a single 2 mg dose of their assigned nicotine replacement therapy in the morning of the treatment visit day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Following a 12-hour nicotine abstinence period, subjects receive a single 2 mg dose of their assigned nicotine replacement therapy in the morning of the treatment visit day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Following a 12-hour nicotine abstinence period, subjects receive a single 2 mg dose of their assigned nicotine replacement therapy in the morning of the treatment visit day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Following a 12-hour nicotine abstinence period, subjects receive a single 2 mg dose of their assigned nicotine replacement therapy in the morning of the treatment visit day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Gum
Description: Following a 12-hour nicotine abstinence period, subjects will be instructed to chew the gum once every 2 seconds, for 30 minutes.
Study: NCT02562066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifampridine phosphate
Description: Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifampridine phosphate
Description: Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo equivalent will be provided as tablets indistinguishable from the amifampridine phosphate tablets. The placebo will be administered consistent with the dose regimen of amifampridine phosphate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo equivalent will be provided as tablets indistinguishable from the amifampridine phosphate tablets. The placebo will be administered consistent with the dose regimen of amifampridine phosphate.
Study: NCT04376658

Intervention type: OTHER
Intervention: COVID-19 Severity
Description: Disease severity characterized by the highest six-level ordinal scale during the hospital stay, which consists of the following categories: a score of 1 indicated not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation; and 6, death

Intervention type: OTHER
Intervention: COVID-19 Severity
Description: Disease severity characterized by the highest six-level ordinal scale during the hospital stay, which consists of the following categories: a score of 1 indicated not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation; and 6, death

Intervention type: OTHER
Intervention: COVID-19 Severity
Description: Disease severity characterized by the highest six-level ordinal scale during the hospital stay, which consists of the following categories: a score of 1 indicated not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation; and 6, death

Intervention type: OTHER
Intervention: COVID-19 Severity
Description: Disease severity characterized by the highest six-level ordinal scale during the hospital stay, which consists of the following categories: a score of 1 indicated not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation; and 6, death

Intervention type: OTHER
Intervention: COVID-19 Severity
Description: Disease severity characterized by the highest six-level ordinal scale during the hospital stay, which consists of the following categories: a score of 1 indicated not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation; and 6, death
Study: NCT02654028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autotransfusion
Description: These group of patients will receive autotransfusion before liver resection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: These group of patients will not receive autotransfusion before liver resection.
Study: NCT03942601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temsirolimus
Description: Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temsirolimus and dexamethasone sodium phosphate
Description: Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2
Study: NCT01026194

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo / Teneli (Teneligliptin) + pio (pioglitazone)
Description: Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneli / Teneli + pio
Description: Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
Study: NCT01867918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation, microwave, radiation therapy
Description: Radiofrequency ablation Microwave ablation Radiation therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Chemotherapy
Study: NCT06011447

Intervention type: OTHER
Intervention: Device to view the skin
Description: Application of device to help view the wound area better
Study: NCT00546663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled 7% hypertonic saline (HS)
Description: 7% hypertonic saline administered twice daily for 14 days by nebulization.~A Pari Sprint Junior nebulizer equipped with a Pari Baby face mask and a Pari Proneb compressor will be used to administer the HS (PARI Respiratory Equipment, Inc., Midlothian, VA).~To minimize the risk of cough and bronchospasm with HS inhalation, infants will be pre-treated prior to each dose of HS with albuterol by metered dose inhaler
Study: NCT03505970

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate in powder form ingested in gelatine capsules. This leads to an increase bicarbonate concentration in blood, increasing buffering capacity which may lead to improvements in exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin will be used as a placebo as it will not lead to any increases in circulating bicarbonate and, at this dose, will not likely have any physiological effect.
Study: NCT00618488

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic BB12 - Bifidobacterium lactis
Description: Bifidobacterium lactis (3.1 oz yogurt) administered once a day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered once a day for 6 weeks
Study: NCT02498392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279
Description: JNJ-42165279 will be administered orally at a dose of 25 milligrams (mg) tablet once daily for 6 weeks.
Study: NCT06304064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Cardiosphere-Derived Cells (CAP-1002)
Description: Intravenous infusion delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002; 75 million CDCs)
Study: NCT02247167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adenotonsillectomy
Description: adenotonsillectomy in children with OSAS and adenotonsillar hypertrophy.
Study: NCT03582254

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]-FDG PET/MR
Description: \[18F\]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital:~* prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine and cytarabine) (PET#1),~* after two chemotherapy cycles (PET#2),~* at the end of the first-line chemotherapy regimens (PET#3).
Study: NCT01639599

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone iv injection
Description: Dexamethasone 5mg iv during anesthesia induction
Study: NCT00544219

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rituximab
Description: 375 mg/m2 i.v. per cycle

Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Description: 750 mg/m2 i.v. per cycle
Study: NCT01639599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, haloperidol
Description: dexamethasone + haloperidol 1mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, haloperidol
Description: Active Comparator: dexamethasone + haloperidol 2mg
Study: NCT00303602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual orally disintegrating olanzapine (SODO)
Description: 5 to 20mg dose, supplied in 5mg tablet strength, tablet should be placed under tongue for at least 60 seconds, daily for 16 weeks.
Study: NCT00544219

Intervention type: DRUG
Group type: OTHER
Intervention: doxorubicin hydrochloride
Description: 50 mg/m2 i.v. per cycle

Intervention type: DRUG
Group type: OTHER
Intervention: prednisone
Description: 100 mg/day p.o. per cycle
Study: NCT00303602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral olanzapine
Description: 5 to 20mg dose, supplied in 5mg tablet strength, oral administration (tablets swallowed), daily for 16 weeks.
Study: NCT01030731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Description: Ceftobiprole 250mg single dose over 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftobiprole
Description: Ceftobiprole 250mg single dose over 2 hours.
Study: NCT00544219

Intervention type: DRUG
Group type: OTHER
Intervention: vincristine sulfate
Description: 1.4 mg/m2 (max. 2.0 mg) i.v. per cycle
Study: NCT02498392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279
Description: JNJ-42165279 will be administered orally at a dose of 25 milligrams (mg) tablet once daily for 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered orally.
Study: NCT00544219

Intervention type: PROCEDURE
Group type: OTHER
Intervention: positron emission tomography
Description: PET Scan during treatment
Study: NCT05447481

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chicory inulin-type fructan
Description: Dietary supplement: chicory inulin-type fructan

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chicory inulin-type fructan
Description: Dietary supplement: chicory inulin-type fructan
Study: NCT02244827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 2349
Description: levonadifloxacin (active drug) and the sulfate metabolite
Study: NCT02498392

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered orally.
Study: NCT04211831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URO-902
Description: intradetrusor injection
Study: NCT04476641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CELL
Description: inject the DC-CIK(dendritic cell activated and cytokine induced killer cell)
Study: NCT04583410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day
Study: NCT03614325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Immersive Relaxation
Description: The software developed by VRHealth allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
Study: NCT04583410

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: PLACEBO OF NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day
Study: NCT04211831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URO-902
Description: intradetrusor injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intradetrusor injection
Study: NCT03929640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 650 mg tablet every 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet every 6 hours
Study: NCT02879968

Intervention type: OTHER
Intervention: Non-interventional study
Study: NCT00496574

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novo Helisen Depot, Phostal
Description: subcutaneous immunotherapy
Study: NCT03495596

Intervention type: DEVICE
Intervention: Videolaryngoscopy
Description: Videolaryngoscopy device type
Study: NCT03374982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DentalVibe
Description: The DentalVibe is a handheld device that delivers vibration to the tissue during local anesthetic administration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DentalVibe
Description: The DentalVibe is a handheld device that delivers vibration to the tissue during local anesthetic administration.
Study: NCT04085120

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection
Description: Distal glossopharyngeal nerve in the neck will be blocked by using 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 10% lignocaine injection
Description: Distal glossopharyngeal nerve in the neck will be blocked by using 10% lignocaine injection
Study: NCT03914131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xinnaoning Capsule
Description: Xinnaoning Capsule used in study group(treatment period) is the true drug that the investigators are to evaluate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Xinnaoning Capsule Simulator
Description: Xinnaoning Capsule Simulator used in control group and introduction period(both groups) is the placebo to reduce the risk of bias.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xinnaoning Capsule Simulator
Description: Xinnaoning Capsule Simulator used in control group and introduction period(both groups) is the placebo to reduce the risk of bias.
Study: NCT03929640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 600 mg tablet every 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 600 mg tablet every 6 hours
Study: NCT00948896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole (TS; TMP/SMX)
Description: daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfadoxine-pyrimethamine (SP)
Description: monthly dosing given as a single dose, 500mg/25mg tabs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DP)
Description: monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs
Study: NCT00631228

Intervention type: DEVICE
Intervention: XIENCE V® Everolimus Eluting Coronary Stent
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease
Study: NCT03846895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microablative Fractional CO2 laser
Description: 3 therapies intravaginally administered will be applied at monthly intervals

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Microablative Fractional CO2 laser
Description: 3 therapies intravaginally administered will be applied at monthly intervals
Study: NCT02615158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Physical Activity and Nutrition
Description: At each session, mothers will identify a dietary goal for the next session (e.g., reduce soda intake). They will learn to track and evaluate their progress, setting new goals or modifying existing ones as necessary. Mothers will be given pedometers and shown how to keep a pedometer tracking chart. As with dietary choice, our objective is to have the mothers identify personal goals and strategies to achieve those goals, so they are more likely to continue to engage in physical activity after the intervention ends.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting
Description: Behavior and Development Related to Diet and Physical Activity. The toddler parenting intervention will include modules on toddler behavior and development. We will devote sessions to topics involving parenting toddlers, limit setting, and child development.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Safety
Description: The intervention will focus on child safety issues, including car seat safety, fire safety, fall prevention, and poison prevention. Participants will set weekly child safety goals.
Study: NCT04374604

Intervention type: DIAGNOSTIC_TEST
Intervention: Placental growth factor
Description: On admission, the blood samples of consenting participants will be collected and analysed using enzyme linked immunosorbent assay technique to determine the level of PlGF (pg/ml).
Study: NCT04052425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study: NCT00722462

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Description: Acupuncture 25 minutes before and after embryo transfer

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Acupuncture at neutral points, 25 minutes before and after embryo transfer
Study: NCT06187454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a method for noninvasive brain stimulation, where a weak electrical current is delivered through two scalp electrodes by a portable battery-powered stimulator.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial direct current stimulation
Description: For sham tDCS, the electrode positions and stimulation parameters will be the same as that used for anodal stimulation except that the current will be delivered only for the initial 30 seconds.
Study: NCT04211831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intradetrusor injection
Study: NCT00928863

Intervention type: OTHER
Intervention: implementation aids
Description: testing a taylor made strategy for implementation NVOG guideline and MOET instruction in 3 hospitals
Study: NCT03953651

Intervention type: OTHER
Intervention: Follow-up
Description: Onset of Major Adverse Cardiovascular Event of death from all causes will be collected at 3 and 6 months after inclusion.
Study: NCT03114150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness training
Description: Physical exercise of moderate intensity designed to improve cardiorespiratory fitness

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional fitness training
Description: Physical exercise of light intensity designed to improve functional fitness
Study: NCT01054443

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT02435524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A&T infant and young child feeding intervention
Description: 1. Interpersonal communication delivered by community workers and volunteers during home visits and at monthly mother's group meetings to:~   * Increase mother's knowledge about optimal breastfeeding and its benefits~  * Increase mother's self-efficacy related to breastfeeding~  * Improve mother's perceptions about social norms relating to breastfeeding~2. Community mobilisation activities to:~   - Raise awareness of the benefits of optimal breastfeeding among opinion leaders, and family members, and increase the support they provide to breastfeeding mothers~3. Enhanced training of government health workers in infant and young child feeding to:~   * Improve their ability to support mothers and provide timely information about infant feeding
Study: NCT00247676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib (SU011248)
Description: Sunitinib 50 mg by oral capsule, daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
Study: NCT00850811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 (ingenol mebutate) Gel
Description: PEP005 (ingenol mebutate) Gel, 0.01%